Drug search by name

AccessPak for HIV PEP Expanded with Viracept and Liver disease

Result of checking the interaction of drug AccessPak for HIV PEP Expanded with Viracept and disease Liver disease for safety when used together.

Check result:

AccessPak for HIV PEP Expanded with Viracept <> Liver disease

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Nelfinavir is primarily metabolized by the liver. Patients with liver disease may be at greater risk for adverse effects from nelfinavir due to decreased drug clearance. Therapy with nelfinavir should be administered cautiously in patients with liver disease.

References:

Sommadossi JP "HIV protease inhibitors: pharmacologic and metabolic distinctions." AIDS 13 (1999): s29-40
"Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.

AccessPak for HIV PEP Expanded with Viracept

Generic Name: emtricitabine / nelfinavir / tenofovir

Brand Name: AccessPak for HIV PEP Expanded with Viracept

Synonyms: n.a.

What is AccessPak for HIV PEP Expanded with Viracept?

Another drug Delete

AccessPak for HIV PEP Expanded with Viracept <> Liver disease

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

Consumer:

There are no data concerning the use of tenofovir disoproxil fumarate in patients with hepatic impairment. Tenofovir and tenofovir disoproxil are not metabolized by liver enzymes. However, since tenofovir is not entirely eliminated by the kidney (70% to 80%), tenofovir pharmacokinetics may be altered in patients with impaired hepatic function.

References: